期刊文献+

HPLC法测定维格列汀原料药中的有关物质 被引量:5

Determination of related substances in vildagliptin by HPLC
原文传递
导出
摘要 目的:建立维格列汀原料药有关物质的HPLC测定方法。方法:采用Agilent Eclipse Plus C18色谱柱(4.6 mm×250 mm,5μm)对降解杂质和工艺杂质进行定量分析,以10 mmol·L^(-1)辛烷磺酸钠(加入0.1%磷酸调pH至2.1)-乙腈为流动相,梯度洗脱,流速1.0 m L·min^(-1),检测波长为210 nm。结果:主峰与各杂质峰间能达到基线分离,维格列汀质量浓度在1.521 0~20.280μg·m L^(-1)范围内与峰面积呈良好的线性关系(r=0.999 8),最低检测限为0.5μg·m L^(-1);3批样品有关物质测定结果显示,已知杂质含量均低于0.1%。结论:方法学验证结果表明,本法可作为维格列汀质量控制的方法。 Objective:To establish an HPLC method for determination of the related substances in vildagliptin.Methods:The test for degradation and process impurities was based on an Agilent Eclipse Plus C18(4.6 mm×250 mm,5 μm)column;the mobile phase consisted of 10 mmol·L-(-1) sodium octanesulfonate solution(adjusted to pH 2.1 with 0.1% phosphoric acid)-acetonitrile with gradient elution at the flow rate of 1.0 m L·min-(-1);the detection wavelength was 210 nm.Results:Chief peak and every impurity peak were separated well.A good linearity was observed over the range of 1.521 0-20.280 μg·m L-(-1)(r=0.999 8),the LOD was 0.5 μg·m L-(-1);The determination results of the three batch of samples showed that the impurity were less than 0.1%.Conclusion:Methodology validation results proved that the established determination method can be used for quality control of vildagliptin.
出处 《药物分析杂志》 CAS CSCD 北大核心 2016年第7期1252-1257,共6页 Chinese Journal of Pharmaceutical Analysis
关键词 维格列汀 二肽基肽酶-4(DPP-4)抑制剂 中间体 副产物 降解杂质 工艺杂质 仿制工艺 有关物质来源 高效液相色谱法 方法学验证 vildagliptin dipeptide peptidase-4(DPP-4)inhibitor intermediates by-products degradation impurities process impurities synthetic processing source of related substances HPLC methodology validation
  • 相关文献

参考文献4

二级参考文献49

  • 1李聪然,游雪甫,蒋建东.糖尿病动物模型及研究进展[J].中国比较医学杂志,2005,15(1):59-63. 被引量:93
  • 2Yang W,Lu J,Wang J,et al.Prevalence of diabetes among men and women in China[J].N Eng J Med,2010,362:1090-1101.
  • 3Holman RR,Paul SK,Bethel MA,et al.10-year follow-up of intensive glucose control in type 2 diabetes[J].N Eegl J Med,2010,362:1090-1101.
  • 4Neumiller JJ.Differential chemistry (structure),machanismof antion,and pharmacology of GLP-1 peceptoragonists and DPP-4 inhibitors[J].J AM Pharm Assoc,2009,49 (Suppl):16-29.
  • 5Ahrén B,Schweizer A,Dejager S,et al.Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans[J].Diabetes Obes Metab,2011,13:775-783.
  • 6Pratley RE,Schweizer A,Rosenstock J,et al.Robust improvements in fasting and prandial measures of B-cell function with vidagliptin in drug-native patients:analysis of pooled vidagliptin monotherapy database[J].Diabetes Obes Metab,2008,10:931-938.
  • 7Tanp P,Yin H,Smith T,et al.Disposition of LAF237 in rats and huma-ns[J].Drug Metab Rev,2002,34(Suppl):147.
  • 8Villhanuer Brinkman JA,Naderi GB,et al.I-[(3-hydro-Xy-1-adamanyI) amino]acet-yI]-2-cyano-(S)-pyrrolidine ; a potent,selective,and orally bi-oavaiable dipeptidy1 peptidase Ⅳ inhibitor with antihyper glycemic pro-perties[J].J Med Chem,2003,46 (13):2774-2789.
  • 9Ahren B,Foley JE,Bosi E.Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin[J].Diabetes Obes metab,2011,13:193-203.
  • 10Pi-Sunyer FX,Schweizer A,Mills D,et al.Efficacy and tolerability of vildagliptin monotherapy in drug-naive patient with type 2 diabetes[J].Diabetes Res Clin pract,2007,76 (1):132-138.

共引文献37

同被引文献33

引证文献5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部